Hormone and reproductive factors and risk of systemic lupus erythematosus: a Mendelian randomized study
- PMID: 38581614
- DOI: 10.1007/s12026-024-09470-z
Hormone and reproductive factors and risk of systemic lupus erythematosus: a Mendelian randomized study
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune and inflammatory disease with a risk associated with hormonal and reproductive factors. However, the potential causal effects between these factors and SLE remain unclear. A two-sample Mendelian randomization study was conducted using the published summary data from the genome-wide association study database. Five independent genetic variants associated with hormonal and reproductive factors were selected as instrumental variables: age at menarche, age at natural menopause, estradiol, testosterone, and follistatin. To estimate the causal relationship between these exposure factors and disease outcome, we employed the inverse-variance weighted, weighted median, and MR-Egger methods. In addition, we carried out multiple sensitivity analyses to validate model assumptions. Inverse variance weighted showed that there was a causal association between circulating follistatin and SLE risk (OR = 1.38, 95% CI 1.03 to 1.86, P = 0.033). However, no evidence was found that correlation between AAM (OR = 1.04, 95% CI 0.77 to 1.40, P = 0.798), ANM (OR = 0.99, 95% CI 0.92 to 1.06, P = 0.721), E2 (OR = 1.40, 95% CI 0.14 to 13.56, P = 0.772), T (OR = 1.25, 95% CI 0.70 to 2.28, P = 0.459), and SLE risk. Our study revealed that elevated circulating follistatin associates with an increased risk of SLE. This finding suggests that the regulatory signals mediated by circulating follistatin may provide a potential mechanism relevant to the treatment of SLE.
Keywords: Age at menarche; Age at natural menopause; Estradiol; Follistatin; Systemic lupus erythematosus; Testosterone.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Durcan L, O’Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332–43. https://doi.org/10.1016/S0140-6736(19)30237-5 . - DOI - PubMed
-
- Fortuna G, Brennan MT. Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management. Dent Clin North Am. 2013;57(4):631–55. https://doi.org/10.1016/j.cden.2013.06.003 . - DOI - PubMed
-
- Rees F, Doherty M, Grainge M, et al. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. Ann Rheum Dis. 2016;75(1):136–41. https://doi.org/10.1136/annrheumdis-2014-206334 . - DOI - PubMed
-
- Singh JA. In-hospital mortality reduction in systemic lupus erythematosus over 2 decades varied by patient sex and age. Clin Rheumatol. 2021;40(3):1201–3. https://doi.org/10.1007/s10067-020-05563-w . - DOI - PubMed
-
- Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2018;32(2):188–205. https://doi.org/10.1016/j.berh.2018.09.004 . - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
